Hematologia
Identificação de mieloma múltiplo de alto risco com um perfil transcriptômico de célula plasmática leucemia-like.
24 Mai, 2022 | 11:21h
Comentário no Twitter
A transcriptomic primary plasma cell leukaemia classifier comprising 53 genes had a sensitivity of 93% in pts with newly-diagnosed MM. Multivariate analysis confirmed the prognostic performance of this classifier vs the International Staging System: https://t.co/bD45PQG9bl #MMSM
— NatureRevClinOncol (@NatRevClinOncol) April 7, 2022
Estudo randomizado | Adição de elotuzumabe à lenalidomida e à dexametasona para pacientes com mieloma múltiplo recém-diagnosticado e inelegível a transplante.
20 Mai, 2022 | 13:36hAddition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial – The Lancet Haematology (link para o resumo – $ para o texto completo)
Comentário: Elotuzumab Does Not Improve PFS in Newly Diagnosed Multiple Myeloma – Cancer Therapy Adviser
Comentário no Twitter
NEW research— Addition of elotuzumab to lenalidomide and dexamethasone did not improve progression-free survival in patients w/ newly diagnosed, transplantation ineligible multiple myeloma: results of the ph3 ELOQUENT-1 trial #mmsm https://t.co/8O3O6ikCJO pic.twitter.com/qe5V7Om9DN
— The Lancet Haematology (@TheLancetHaem) May 12, 2022
Revisão | Papel dos anticoagulantes orais diretos na profilaxia de tromboembolismo venoso pós-operatório.
19 Mai, 2022 | 12:57h
Comentário no Twitter
Our work on this review summarises the pharmacological profile of DOACs and highlights the use of #DOACs in post-operative #VTE prophylaxis based on the available clinical trialhttps://t.co/7MRvWBfaEG @radcliffeCARDIO @mmamas1973 @AnastasiaSMihai @mirvatalasnag @KardiologieHH pic.twitter.com/MW6n2CWGe0
— Henry Han, MBBS, MD (@HanCardiomd) May 13, 2022
Sob licença de CC-BY-NC 4.0
Série “Como Tratar” sobre discrasias de células plasmáticas.
19 Mai, 2022 | 12:39hEditorial: Introduction to a How I Treat series on plasma cell dyscrasias – Blood
How I treat relapsed multiple myeloma – Blood
How I treat frontline transplantation-eligible multiple myeloma – Blood
Sinopse de diretriz | Terapia antitrombótica para tromboembolismo venoso.
18 Mai, 2022 | 17:04hAntithrombotic Therapy for Venous Thromboembolism – JAMA (gratuito por tempo limitado)
Diretriz original: Antithrombotic Therapy for VTE Disease
Second Update of the CHEST Guideline and Expert Panel Report
Estudo de coorte | Trombose venosa ou arterial e mortes em casos de COVID-19.
18 Mai, 2022 | 16:58hComentário convidado: Risk of arterial and venous thromboses after COVID-19 – The Lancet Infectious Diseases
Comunicado de imprensa: COVID-19’s high blood clot risk – University of Oxford
Comentário no Twitter
Clots with Covid: Multi-national report of over 900,000 people indicates propensity of risk for arterial and venous thrombi is in men, with increasing age, and association with fatalities (4-fold in non-hospitalized) https://t.co/muGnDld4Um pic.twitter.com/6bLiHPLInm
— Eric Topol (@EricTopol) May 13, 2022
Sob licença de Creative Commons Attribution (CC BY 4.0)
Estudo de coorte | Sustentabilidade de uma intervenção de apoio a decisão clínica voltada para estimular o cuidado ambulatorial de pacientes selecionados com embolia pulmonar aguda.
18 Mai, 2022 | 16:45hConteúdo relacionado: Outpatient versus inpatient treatment for acute pulmonary embolism – Cochrane Library
Comentário no Twitter
This multicenter cohort study of ED patients with acute pulmonary embolism found the initial increase in outpatient management from a physician champion-led, EHR-embedded clinical decision support intervention was sustained 4 years later. https://t.co/UPf8pAOTry
— JAMA Network Open (@JAMANetworkOpen) May 16, 2022
Estudo randomizado | Ibrutinibe-venetoclax com duração fixa em pacientes com leucemia linfocítica crônica e comorbidades.
17 Mai, 2022 | 11:48h
Comentário no Twitter
In older patients and/or those with comorbidities with untreated #CLL, treatment with ibrutinib-venetoclax was superior to chlorambucil-obinutuzumab, with fewer events and longer PFS after just over 2 yrs of follow-up. Read about the GLOW trial: https://t.co/gYjksIhp96
#LeuSM pic.twitter.com/aBnpdeKhFO— NEJM Evidence (@NEJMEvidence) May 13, 2022